[go: up one dir, main page]

RU2018115716A - Пиранодипиридиновое соединение - Google Patents

Пиранодипиридиновое соединение Download PDF

Info

Publication number
RU2018115716A
RU2018115716A RU2018115716A RU2018115716A RU2018115716A RU 2018115716 A RU2018115716 A RU 2018115716A RU 2018115716 A RU2018115716 A RU 2018115716A RU 2018115716 A RU2018115716 A RU 2018115716A RU 2018115716 A RU2018115716 A RU 2018115716A
Authority
RU
Russia
Prior art keywords
pyrano
dipyridin
dihydro
oxo
fluoro
Prior art date
Application number
RU2018115716A
Other languages
English (en)
Other versions
RU2743998C2 (ru
RU2018115716A3 (ru
Inventor
Тосики КУРОКАВА
Ю Йосида
Когиоку ШИН
Йосихиса КОБАЯСИ
Хиронори ФУКУМОТО
Кунитоси ТАКЕДА
Йосиаки ОХАСИ
Макото КОТАКЕ
Томоюки СИБУГУТИ
Тору ВАТАНАБЕ
Йоити КИТА
Синсуке ХИРОТА
Такаси ФУКУЯМА
Ясуаки КАМАДА
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2018115716A publication Critical patent/RU2018115716A/ru
Publication of RU2018115716A3 publication Critical patent/RU2018115716A3/ru
Application granted granted Critical
Publication of RU2743998C2 publication Critical patent/RU2743998C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (83)

1. Соединение, выбранное из группы, состоящей из
9-(2-хлорфенил)-7-(пиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000001
2-фтор-6-(7-(5-метоксипиридин-3-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000002
2-фтор-6-(7-(6-метилпиридин-3-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000003
9-(2-хлор-3-фторфенил)-7-(6-метилпиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000004
2-фтор-6-(7-(2-метоксипиримидин-5-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000005
7-(пиридин-3-ил)-9-(2,3,5,6-тетрафторфенил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000006
3-(8-оксо-7-(тиофен-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрила:
Figure 00000007
3-(8-оксо-7-(тиофен-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиразин-2-карбонитрила:
Figure 00000008
9-(2-фторфенил)-7-фенил-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000009
2-(7-(4-фторфенил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000010
3-(7-(4-фторфенил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрила:
Figure 00000011
3-(7-(2-фторфенил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрила:
Figure 00000012
3-(3-фтор-8-оксо-7-фенил-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрила:
Figure 00000013
2-фтор-6-(3-фтор-8-оксо-7-(пиридин-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000014
2-фтор-6-(7-(5-фторпиридин-3-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000015
2-фтор-6-(10-фтор-3-оксо-4-(пиридин-3-ил)-4,5-дигидро-3H-хромено[3,4-b]пиридин-2-ил)бензонитрила:
Figure 00000016
9-(2-хлор-3-фторфенил)-7-(5-фторпиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000017
2-фтор-6-(8-оксо-7-(пиримидин-5-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000018
3,6-дифтор-2-(8-оксо-7-(пиридин-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000019
2-(7-(5-хлорпиридин-3-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)-6-фторбензонитрила:
Figure 00000020
2-фтор-6-(7-(2-метилпиримидин-5-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрила:
Figure 00000021
и
9-(3-фтор-2-метилфенил)-7-(пиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-она:
Figure 00000022
или его фармацевтически приемлемая соль.
2. 9-(2-Хлорфенил)-7-(пиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-он:
Figure 00000001
или его фармацевтически приемлемая соль.
3. 2-Фтор-6-(7-(6-метилпиридин-3-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000003
или его фармацевтически приемлемая соль.
4. 9-(2-Хлор-3-фторфенил)-7-(6-метилпиридин-3-ил)-6H-пирано[3,2-b:5,4-b']дипиридин-8(7H)-он:
Figure 00000023
или его фармацевтически приемлемая соль.
5. 2-Фтор-6-(7-(2-метоксипиримидин-5-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000024
или его фармацевтически приемлемая соль.
6. 3-(7-(4-Фторфенил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрил:
Figure 00000011
или его фармацевтически приемлемая соль.
7. 3-(3-Фтор-8-оксо-7-фенил-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)пиколинонитрил:
Figure 00000013
или его фармацевтически приемлемая соль.
8. 2-Фтор-6-(3-фтор-8-оксо-7-(пиридин-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000014
или его фармацевтически приемлемая соль.
9. 2-Фтор-6-(8-оксо-7-(пиримидин-5-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000018
или его фармацевтически приемлемая соль.
10. 3,6-Дифтор-2-(8-оксо-7-(пиридин-3-ил)-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000019
или его фармацевтически приемлемая соль.
11. 2-Фтор-6-(7-(2-метилпиримидин-5-ил)-8-оксо-7,8-дигидро-6H-пирано[3,2-b:5,4-b']дипиридин-9-ил)бензонитрил:
Figure 00000021
или его фармацевтически приемлемая соль.
12. Фармацевтическая композиция, содержащая в качестве активного ингредиента соединение по любому из пп. 1-11 или его фармацевтически приемлемую соль.
13. Фармацевтическая композиция по п. 12, которая представляет собой ингибитор AMPA-рецептора.
14. Фармацевтическая композиция по п. 12 для лечения эпилепсии.
15. Фармацевтическая композиция по п. 14 где эпилепсия представляет собой парциальную эпилепсию.
16. Соединение по любому из пп. 1-11 или его фармацевтически приемлемая соль, применяемые для лечения эпилепсии.
17. Соединение по п. 16 или его фармацевтически приемлемая соль, где эпилепсия представляет собой парциальную эпилепсию.
RU2018115716A 2015-11-13 2016-11-09 Пиранодипиридиновое соединение RU2743998C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-222805 2015-11-13
JP2015222805 2015-11-13
PCT/JP2016/083211 WO2017082288A1 (ja) 2015-11-13 2016-11-09 ピラノジピリジン化合物

Publications (3)

Publication Number Publication Date
RU2018115716A true RU2018115716A (ru) 2019-12-13
RU2018115716A3 RU2018115716A3 (ru) 2020-02-06
RU2743998C2 RU2743998C2 (ru) 2021-03-01

Family

ID=58691331

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018115716A RU2743998C2 (ru) 2015-11-13 2016-11-09 Пиранодипиридиновое соединение

Country Status (24)

Country Link
US (1) US9738656B2 (ru)
EP (1) EP3378863A4 (ru)
JP (1) JP6353173B2 (ru)
KR (1) KR20180080201A (ru)
CN (1) CN108349989B (ru)
AR (1) AR106647A1 (ru)
AU (1) AU2016351424B2 (ru)
BR (1) BR112018008006A2 (ru)
CA (1) CA3002930A1 (ru)
CL (1) CL2018001067A1 (ru)
CO (1) CO2018004213A2 (ru)
HK (1) HK1255832A1 (ru)
IL (1) IL258952B (ru)
JO (1) JO3742B1 (ru)
MA (1) MA43275A (ru)
MX (1) MX380080B (ru)
MY (1) MY185971A (ru)
PE (1) PE20181008A1 (ru)
PH (1) PH12018500903A1 (ru)
RU (1) RU2743998C2 (ru)
SG (1) SG11201803433TA (ru)
TW (1) TWI644916B (ru)
UA (1) UA122241C2 (ru)
WO (1) WO2017082288A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019132958A (ru) * 2017-05-09 2021-06-09 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство, содержащее пиранодипиридиновое соединение
US20210323972A1 (en) * 2017-05-09 2021-10-21 Eisai R&D Management Co., Ltd. Crystals of pyranodipyridine compound
EP3658167A1 (en) * 2017-07-26 2020-06-03 HG&H Pharmaceuticals (Pty) Limited Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases
US11407748B2 (en) 2017-10-06 2022-08-09 Takeda Pharmaceutical Company Limited Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
ES2971497T3 (es) 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
JP7265526B2 (ja) 2018-03-20 2023-04-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 てんかん治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511569A (en) * 1982-08-26 1985-04-16 Schering Corporation Tricyclic lactams and derivatives useful in increasing cardiac contractility
EP0102046A1 (en) * 1982-08-26 1984-03-07 Schering Corporation Tricyclic lactams, method for making them, pharmaceutical compositions containing them
US4666916A (en) 1985-11-08 1987-05-19 Ciba-Geigy Corporation Hexahydro-(1)-benzo-(pyrano and thiopyrano) (4,3-C)pyridines, useful as serotin-2 blocking agents
FR2717811B1 (fr) * 1994-03-28 1996-04-26 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
CN1245386C (zh) * 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
HU228961B1 (en) * 2000-09-18 2013-07-29 Eisai R & D Man Co Triazinones and their use as active ingredients of pharmaceutical compositions
RU2279428C2 (ru) * 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов

Also Published As

Publication number Publication date
IL258952A (en) 2018-06-28
MA43275A (fr) 2018-09-26
KR20180080201A (ko) 2018-07-11
PE20181008A1 (es) 2018-06-26
IL258952B (en) 2021-01-31
US20170137436A1 (en) 2017-05-18
MX2018004979A (es) 2018-09-07
UA122241C2 (uk) 2020-10-12
EP3378863A1 (en) 2018-09-26
HK1255832A1 (zh) 2019-08-30
PH12018500903A1 (en) 2018-11-05
AU2016351424A8 (en) 2018-06-14
US9738656B2 (en) 2017-08-22
SG11201803433TA (en) 2018-05-30
MX380080B (es) 2025-03-11
CN108349989B (zh) 2021-01-01
MY185971A (en) 2021-06-14
JO3742B1 (ar) 2021-01-31
RU2743998C2 (ru) 2021-03-01
TW201720829A (zh) 2017-06-16
TWI644916B (zh) 2018-12-21
AU2016351424B2 (en) 2020-06-25
EP3378863A4 (en) 2019-03-06
JPWO2017082288A1 (ja) 2017-12-21
AR106647A1 (es) 2018-02-07
AU2016351424A1 (en) 2018-05-10
CN108349989A (zh) 2018-07-31
JP6353173B2 (ja) 2018-07-04
CO2018004213A2 (es) 2018-07-10
RU2018115716A3 (ru) 2020-02-06
CL2018001067A1 (es) 2018-07-20
WO2017082288A1 (ja) 2017-05-18
CA3002930A1 (en) 2017-05-18
BR112018008006A2 (pt) 2018-10-30

Similar Documents

Publication Publication Date Title
RU2018115716A (ru) Пиранодипиридиновое соединение
HRP20191307T1 (hr) Spojevi heteroaril-piridona i aza-piridona kao inhibitori aktivnosti btk
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
EP3500575A4 (en) CRYSTALLINE FORM OF ((S) -7- (1-ACRYLOYLPIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRA-HYDROPYRAZOLO [1,5-A] PYRIMIDIN-3- CARBOXAMIDE, PRODUCTION AND USE THEREOF
PE20170693A1 (es) Derivados de imidazol pentaciclicos fusionados
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
JP2014513139A5 (ru)
JP2016537384A5 (ru)
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
LT3873884T (lt) 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
JP2016515098A5 (ru)
HRP20211864T1 (hr) Inhibitori hetero-halo histonske deacetilaze
PE20170321A1 (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos
PE20141938A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MA55402A (fr) Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie
NZ622072A (en) Synthetic methods for spiro-oxindole compounds
MX392531B (es) Formas morficas de g1t38 y metodos de preparacion de las mismas.
PL2935274T3 (pl) Pochodne 3-okso-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pirymidyny do leczenia chorób układu oddechowego
CL2019001454A1 (es) Productos combinados para el tratamiento del vsr (divisional de la solicitud n°1808-2018).
CL2014002686A1 (es) Compuestos derivados de 4-amino-6[metil(quinolin/quinoxalin)-il)amino]pirimidin-5-carbonitrilo, moduladores de pi3k; composicion farmaceutica; y su uso para el tratamiento de una enfermedad seleccionada de artritis reumatoide, espondilitis anquilosante, osteoartritis, psoriasis, enfermedades inflamatorias o autoinmunes.
EP3842434A4 (en) CRYSTAL POLYMORPH OF 8-BROMO-2-(1-METHYLPIPERIDINE-4-YLAMINO)-4-(4-PHENOXYPHENYLAMINO)PYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF
EP3568400C0 (en) PROCESS FOR PREPARING 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS WITH POSITION 3